DAFNA Capital Management’s Prevail Therapeutics PRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
– Sell
-75,000
Closed -$1.73M – 95
2020
Q4
$1.73M Hold
75,000
– – 0.51% 42
2020
Q3
$764K Hold
75,000
– – 0.25% 62
2020
Q2
$1.12M Hold
75,000
– – 0.32% 53
2020
Q1
$914K Hold
75,000
– – 0.38% 53
2019
Q4
$1.19M Hold
75,000
– – 0.41% 55
2019
Q3
$921K Hold
75,000
– – 0.35% 60
2019
Q2
$990K Buy
+75,000
New +$1.09M 0.37% 59

DAFNA Capital Management's PRVL Position: Q1 2021 in Review

DAFNA Capital Management sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 75,000 shares — an estimated $1.73M sold.

DAFNA Capital Management first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $1.73M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • DAFNA Capital Management reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
  • DAFNA Capital Management sold 75,000 Prevail Therapeutics shares in Q1 2021, an estimated $1.73M.
  • DAFNA Capital Management first reported a position in Prevail Therapeutics in Q2 2019 and held it in 7 quarters.
  • DAFNA Capital Management's Prevail Therapeutics position peaked at $1.73M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.

Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.